Latest market price
67.18
+1.25+1.90%
TA
Loading chart...
Snapshot
| Index | — | P/E | 38.61 | EPS (ttm) | 1.74 | Insider Own | 23.15% | Shs Outstand | 445.28M | Perf Week | 5.20% |
| Market Cap | 29.91B | Forward P/E | 11.56 | EPS next Y | 5.81 | Insider Trans | -0.59% | Shs Float | 417.58M | Perf Month | 16.57% |
| Enterprise Value | 38.04B | PEG | 3.76 | EPS next Q | 1.18 | Short Float | 3.08% | Perf Quarter | 17.51% | ||
| Income | 815.00M | P/S | 11.80 | EPS this Y | 14.85% | Short Ratio | 4.34 | Perf Half Y | 35.80% | ||
| Sales | 2.54B | P/B | 3.06 | EPS next Y | 9.18% | ROA | 4.11% | Short Interest | 12.84M | Perf YTD | 73.86% |
| Book/sh | 21.98 | P/C | 35.74 | EPS next 5Y | 10.28% | ROE | 12.25% | 52W High | 67.71 -0.78% | Perf Year | 83.20% |
| Cash/sh | 1.88 | P/FCF | 10.05 | EPS past 3/5Y | 162.07% 7.06% | ROIC | 8.96% | 52W Low | 36.03 86.46% | Perf 3Y | 146.08% |
| Dividend Est. | 0.94 (1.40%) | EV/EBITDA | 22.18 | Sales past 3/5Y | 2.06% 2.30% | Gross Margin | 89.38% | Volatility | 2.11% 2.17% | Perf 5Y | 79.15% |
| Dividend TTM | 0.93 (1.38%) | EV/Sales | 15.00 | EPS Y/Y TTM | -19.44% | Oper. Margin | 62.34% | ATR (14) | 1.42 | Perf 10Y | — |
| Dividend Ex-Date | Nov 13, 2026 | Quick Ratio | 1.29 | Sales Y/Y TTM | 9.97% | Profit Margin | 32.15% | RSI (14) | 76.73 | Recom | 2.00 |
| Dividend Gr. 3/5Y | 5.01% 24.01% | Current Ratio | 1.29 | EPS Q/Q | 15.79% | SMA20 | 10.39% | Beta | 0.36 | Target Price | 66.50 |
| Payout | 48.95% | Debt/Eq | 0.92 | Sales Q/Q | 16.41% | SMA50 | 11.45% | Rel Volume | 1.51 | Prev Close | 65.93 |
| Employees | 100 | LT Debt/Eq | 0.88 | Earnings | Nov 04 | SMA200 | 26.22% | Avg Volume | 3.08M | Price | 67.18 |
| IPO Date | Jun 16, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.71% 1.85% | Net Debt/EBITDA | 4.74 | Volume | 4,658,146 | Change | 1.90% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-07-26 | Reiterated | Morgan Stanley | Overweight | $65 → $67 |
| Aug-06-26 | Reiterated | Goldman Sachs | Buy | $59 → $66 |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $64 → $65 |
| Apr-21-26 | Reiterated | UBS | Buy | $49 → $57 |
| Apr-10-26 | Reiterated | Morgan Stanley | Overweight | $61 → $63 |
| Feb-27-26 | Reiterated | Seaport Global | $50 | |
| Feb-12-26 | Reiterated | Morgan Stanley | Overweight | $56 → $61 |
| Jan-30-26 | Upgrade | UBS | Neutral → Buy | $28 → $49 |
| Dec-11-25 | Reiterated | Leerink Partners | $45 | |
| Sep-30-25 | Initiated | Goldman Sachs | Buy | $51 → $42 |
Latest News· Times ET
Oct-30-26
Oct-30-2610:16AM
Oct-29-26
Oct-25-26
Oct-25-2610:35AM
Oct-22-26
02:45AM
Oct-16-26
Oct-12-26
Oct-12-2611:18AM
Oct-09-26
Oct-09-2608:50AM
Oct-08-26
Oct-05-26
Oct-03-26
Oct-01-26
Sep-29-26
Sep-29-2612:30PM
Sep-26-26
Sep-26-2604:09AM
Sep-25-26
Sep-25-2602:03AM
Company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,536 | 2,378 | 2,264 | 2,355 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 269 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 2,266 | 2,378 | 2,264 | 2,355 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 604 | 573 | 237 | 250 | — | — | — | — | — | |
| Research and Development | 240 | 452 | 2 | 52 | — | — | — | — | — | |
| Other Operating Expense | -158 | -206 | 732 | 560 | — | — | — | — | — | |
| Operating Income | 1,580 | 1,560 | 1,292 | 1,492 | — | — | — | — | — | |
| Interest Expense | 362 | 308 | 226 | 187 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 130 | 72 | 264 | 395 | — | — | — | — | — | |
| Net Income Before Taxes | 1,349 | 1,324 | 1,331 | 1,700 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 815 | 771 | 859 | 1,135 | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,349 | 1,324 | 1,331 | 1,700 | — | — | — | — | — | |
| Net Income | 815 | 771 | 859 | 1,135 | — | — | — | — | — | |
| EPS (Recurring) | 2.41 | 2.33 | 1.92 | 3.41 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.41 | 2.33 | 1.92 | 3.41 | — | — | — | — | — | |
| EPS (Diluted) | 1.74 | 1.80 | 1.91 | 2.53 | — | — | — | — | — | |
| EBITDA | 1,715 | 1,636 | 1,556 | 1,887 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 38.61 | 21.47 | 13.36 | 11.10 | — | — | — | — | — | |
| Price To Sales Ratio | 11.79 | 7.02 | 5.03 | 5.34 | — | — | — | — | — | |
| Gross Margin | 89.35 | 100.00 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | 62.30 | 65.60 | 57.07 | 63.35 | — | — | — | — | — | |
| Net Margin | 32.14 | 32.42 | 37.94 | 48.20 | — | — | — | — | — | |
| Shares Outstanding | 445 | 432 | 446 | 448 | — | — | — | — | — | |
| Market Capitalization | 29,895 | 16,692 | 11,377 | 12,584 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments | Oct 05 '26 | Sale | 57.10 | 4,126 | 235,595 | 0 | Oct 05 |
| Urist Marshall | EVP, Research & Investments | Sep 28 '26 | Sale | 57.88 | 4,126 | 238,813 | 4,126 | Sep 30 |
| Hite Christopher | EVP & Chairman, Partnering | Sep 22 '26 | Sale | 58.53 | 100,000 | 5,853,095 | 270,401 | Sep 24 |
| Hite Christopher | EVP & Chairman, Partnering | Aug 18 '26 | Sale | 59.97 | 100,000 | 5,997,250 | 370,401 | Aug 19 |
| Coyne Terrance P. | EVP & CFO | Aug 13 '26 | Sale | 58.68 | 11,002 | 645,551 | 0 | Aug 17 |
| Urist Marshall | EVP, Research & Investments | Jul 01 '26 | Sale | 55.88 | 9,099 | 508,454 | 0 | Jul 02 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 30 '26 | Sale | 56.50 | 130,000 | 7,345,471 | 40,000 | Jul 02 |
| Urist Marshall | EVP, Research & Investments | Jun 24 '26 | Sale | 55.18 | 9,098 | 502,067 | 9,099 | Jun 25 |
| Hite Christopher | EVP & Chairman, Partnering | Jun 23 '26 | Sale | 54.40 | 150,000 | 8,159,277 | 559,399 | Jun 25 |
| Coyne Terrance P. | EVP & CFO | May 26 '26 | Sale | 53.98 | 64,399 | 3,476,116 | 0 | May 28 |
| Urist Marshall | EVP, Research & Investments | May 20 '26 | Sale | 52.75 | 13,684 | 721,838 | 18,197 | May 21 |
| Urist Marshall | EVP, Research & Investments | May 14 '26 | Sale | 53.06 | 13,684 | 726,137 | 31,881 | May 15 |
| Norden Gregory | Director | May 14 '26 | Sale | 53.00 | 3,045 | 161,385 | 191,803 | May 15 |
| Coyne Terrance P. | EVP & CFO | Apr 28 '26 | Sale | 49.78 | 34,791 | 1,731,841 | 0 | Apr 30 |
| Coyne Terrance P. | EVP & CFO | Apr 01 '26 | Sale | 48.33 | 34,791 | 1,681,512 | 32,916 | Apr 02 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.